Vergès, Bruno

Pathophysiology of diabetic dyslipidaemia: where are we?

Vergès, B. (2015) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disorders

Cited by 708

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 412

Lipid modification in type 2 diabetes: the role of LDL and HDL

Vergès, B. (2009) · Fundamental & Clinical Pharmacology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 117

Outcome in AN adult patients: A 13-year follow-up in 484 patients

Rigaud, D., Pennacchio, H., Bizeul, C., Reveillard, V., & Vergès, B. (2011) · Diabetes & Metabolism

Eating Disorders and BehaviorsNutrition, Health and Food Behavior

Cited by 98

Self-Monitoring of Blood Glucose in Type 2 Diabetes: Recent Studies

Schnell, O., Alawi, H., Battelino, T., Ceriello, A., Diem, P., Felton, A.-M., Grzeszczak, W., Harno, K., Kempler, P., Satman, I., et al. (2013) · Journal of Diabetes Science and Technology

Diabetes Management and ResearchDiabetes Management and Education

Cited by 88

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus

Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Sberna, A.-L., Petit, J.-M., Degrace, P., & Demizieux, L. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersDiabetes Treatment and Management

Cited by 75

Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study

Borén, J., Watts, G. F., Adiels, M., Söderlund, S., Chan, D. C., Hakkarainen, A., Lundbom, J., Lundbom, N., Matikainen, N., Kahri, J., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 72

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 72

Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 58

Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression

Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Petit, J. M., Degrace, P., & Demizieux, L. (2021) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Cited by 54

Addressing Schemes of Self-Monitoring of Blood Glucose in Type 2 Diabetes: A European Perspective and Expert Recommendation

Schnell, O., Alawi, H., Battelino, T., Ceriello, A., Diem, P., Felton, A., Grzeszczak, W., Harno, K., Kempler, P., Satman, I., et al. (2011) · Diabetes Technology & Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 47

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings

Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 40

Frequent and severe hypoglycaemia detected with continuous glucose monitoring in older institutionalised patients with diabetes

Bouillet, B., Tscherter, P., Vaillard, L., Nonciaux, C., Hourdain, P., Ravier, A., Rouland, A., Petit, J. M., Vergès, B., & Quilot, E. (2021) · Age and Ageing

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 29

Reasons for non-intensification of treatment in people with type 2 diabetes receiving oral monotherapy: Outcomes from the prospective DIAttitude study

Balkau, B., Halimi, S., Blickle, J.-F., Vergès, B., Avignon, A., Attali, C., Chartier, I., & Amelineau, E. (2016) · Annales d'Endocrinologie

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 3